CY1111071T1 - Φαρμακευτικες ενωσεις που περιεχουν τα παραγωγα αζετιδινης, τα νεα παραγωγα αζετιδινης και η παρασκευη τους - Google Patents
Φαρμακευτικες ενωσεις που περιεχουν τα παραγωγα αζετιδινης, τα νεα παραγωγα αζετιδινης και η παρασκευη τουςInfo
- Publication number
- CY1111071T1 CY1111071T1 CY20101101042T CY101101042T CY1111071T1 CY 1111071 T1 CY1111071 T1 CY 1111071T1 CY 20101101042 T CY20101101042 T CY 20101101042T CY 101101042 T CY101101042 T CY 101101042T CY 1111071 T1 CY1111071 T1 CY 1111071T1
- Authority
- CY
- Cyprus
- Prior art keywords
- azetidin
- producers
- preparation
- compounds containing
- pharmaceutical compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 title 2
- 150000003839 salts Chemical class 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
Η παρούσα εφεύρεση αφορά τις φαρμακευτικές ενώσεις που περιέχουν ως βασικό δραστικό στοιχείο τουλάχιστον μία ένωση του τύπου όπου το R1 δηλώνει μια ρίζα -N(R4)R5, -N(R4)-CO-R5, -N(R4)-SΟ2R6 ή ένα από τα φαρμακευτικώς αποδεκτά άλατα αυτών, τα νέα παράγωγα του τύπου (I), τα φαρμακευτικώς αποδεκτά άλατα και την παρασκευή τους.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0002776A FR2805817B1 (fr) | 2000-03-03 | 2000-03-03 | Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation |
EP01909939A EP1263722B1 (fr) | 2000-03-03 | 2001-03-01 | Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1111071T1 true CY1111071T1 (el) | 2015-06-11 |
Family
ID=8847706
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20101101042T CY1111071T1 (el) | 2000-03-03 | 2010-11-18 | Φαρμακευτικες ενωσεις που περιεχουν τα παραγωγα αζετιδινης, τα νεα παραγωγα αζετιδινης και η παρασκευη τους |
Country Status (36)
Country | Link |
---|---|
EP (1) | EP1263722B1 (el) |
JP (1) | JP4883867B2 (el) |
KR (1) | KR100819572B1 (el) |
CN (1) | CN100386314C (el) |
AT (1) | ATE478841T1 (el) |
AU (1) | AU780880B2 (el) |
BG (1) | BG66001B1 (el) |
BR (1) | BR0108893B1 (el) |
CA (1) | CA2400141C (el) |
CY (1) | CY1111071T1 (el) |
CZ (1) | CZ301254B6 (el) |
DE (1) | DE60142891D1 (el) |
DK (1) | DK1263722T3 (el) |
DZ (1) | DZ3312A1 (el) |
EA (1) | EA007109B1 (el) |
EE (1) | EE05103B1 (el) |
ES (1) | ES2351276T3 (el) |
FR (1) | FR2805817B1 (el) |
HR (1) | HRP20020712B1 (el) |
HU (1) | HUP0400636A3 (el) |
IL (2) | IL151321A0 (el) |
MA (1) | MA26880A1 (el) |
ME (1) | MEP9509A (el) |
MX (1) | MXPA02008349A (el) |
NO (1) | NO324524B1 (el) |
NZ (1) | NZ521077A (el) |
OA (1) | OA12222A (el) |
PL (1) | PL208021B1 (el) |
PT (1) | PT1263722E (el) |
SI (1) | SI1263722T1 (el) |
SK (1) | SK287445B6 (el) |
TW (1) | TWI304399B (el) |
UA (1) | UA73554C2 (el) |
WO (1) | WO2001064634A1 (el) |
YU (1) | YU66002A (el) |
ZA (1) | ZA200206912B (el) |
Families Citing this family (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002022579A2 (en) | 2000-09-11 | 2002-03-21 | Sepracor, Inc. | Antipsychotic sulfonamide-heterocycles, and methods of use thereof |
FR2814678B1 (fr) * | 2000-10-04 | 2002-12-20 | Aventis Pharma Sa | Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite |
US20020091114A1 (en) | 2000-10-04 | 2002-07-11 | Odile Piot-Grosjean | Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity |
AU2002319627A1 (en) | 2001-07-20 | 2003-03-03 | Merck And Co., Inc. | Substituted imidazoles as cannabinoid receptor modulators |
FR2833842B1 (fr) * | 2001-12-21 | 2004-02-13 | Aventis Pharma Sa | Compositions pharmaceutiques a base de derives d'azetidine |
CA2478338A1 (en) | 2002-03-08 | 2003-09-18 | Signal Pharmaceuticals, Inc. | Combination therapy for treating, preventing or managing proliferative disorders and cancers |
CA2478183C (en) | 2002-03-12 | 2010-02-16 | Merck & Co. Inc. | Substituted amides |
US7105526B2 (en) | 2002-06-28 | 2006-09-12 | Banyu Pharmaceuticals Co., Ltd. | Benzimidazole derivatives |
WO2004013120A1 (en) | 2002-07-29 | 2004-02-12 | F. Hoffmann-La Roche Ag | Novel benzodioxoles |
DE60322114D1 (de) | 2003-01-02 | 2008-08-21 | Hoffmann La Roche | Pyrrolyl-thiazole und ihre verwendung als inverse agonisten des cb 1 rezeptors |
CA2511859A1 (en) | 2003-01-02 | 2004-07-22 | Alexander Mayweg | Novel cb 1 receptor inverse agonists |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
US7514562B2 (en) * | 2003-03-07 | 2009-04-07 | Glaxo Group Limited | Urea derivatives and their use as vanilloid receptor antagonists in the treatment of pain |
BRPI0409959A (pt) * | 2003-05-01 | 2006-04-25 | Vernalis Res Ltd | uso de derivados de azetidinacarboxamida em terapia |
US20040224962A1 (en) * | 2003-05-09 | 2004-11-11 | Pfizer Inc | Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss |
EP1636181A1 (en) * | 2003-06-11 | 2006-03-22 | Merck & Co., Inc. | Substituted 3-alkyl and 3-alkenyl azetidine derivatives |
KR100809201B1 (ko) | 2003-06-20 | 2008-02-29 | 에프. 호프만-라 로슈 아게 | 카나바노이드 수용체 1 역작용제로서 2-아미노벤조티아졸 |
WO2005028438A1 (ja) | 2003-09-22 | 2005-03-31 | Banyu Pharmaceutical Co., Ltd. | 新規ピペリジン誘導体 |
DE602004011394T2 (de) | 2003-12-08 | 2009-01-08 | F. Hoffmann-La Roche Ag | Thiazolderivate |
ATE478856T1 (de) | 2004-01-28 | 2010-09-15 | Hoffmann La Roche | Spirobenzodioxole und deren verwendung als cb1- antagonisten |
EP1574211A1 (en) | 2004-03-09 | 2005-09-14 | Inserm | Use of antagonists of the CB1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases |
US20080125403A1 (en) | 2004-04-02 | 2008-05-29 | Merck & Co., Inc. | Method of Treating Men with Metabolic and Anthropometric Disorders |
AU2005240734A1 (en) | 2004-05-10 | 2005-11-17 | F. Hoffmann-La Roche Ag | Pyrrole or imidazole amides for treating obesity |
FR2876688B1 (fr) * | 2004-10-14 | 2007-03-16 | Aventis Pharma Sa | Nouveau produit, procede et intermediaires de preparation de derives d'azetidine |
FR2876689B1 (fr) | 2004-10-14 | 2008-02-22 | Aventis Pharma Sa | Nouveau procede et intermediaires de preparation de derives de n-(1-benzhydryl-azetidin-3-yl)-n-phenyl-methylsulfonamide |
ATE399156T1 (de) | 2004-10-27 | 2008-07-15 | Hoffmann La Roche | Neue indol- oder benzimidazol-derivate |
ES2351348T3 (es) | 2004-11-09 | 2011-02-03 | F. Hoffmann-La Roche Ag | Derivados de la dibenzosuberona. |
ES2326280T3 (es) | 2005-04-06 | 2009-10-06 | F. Hoffmann-La Roche Ag | Derivados de piridin-3-carboxamida como agonistas inversos de cb1. |
KR101397913B1 (ko) | 2005-05-30 | 2014-05-26 | 엠에스디 가부시키가이샤 | 신규 피페리딘 유도체 |
US7923465B2 (en) | 2005-06-02 | 2011-04-12 | Glenmark Pharmaceuticals S.A. | Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation |
WO2007018248A1 (ja) | 2005-08-10 | 2007-02-15 | Banyu Pharmaceutical Co., Ltd. | ピリドン化合物 |
AU2006282260A1 (en) | 2005-08-24 | 2007-03-01 | Msd K.K. | Phenylpyridone derivative |
AU2006288153A1 (en) | 2005-09-07 | 2007-03-15 | Msd K.K. | Bicyclic aromatic substituted pyridone derivative |
EP1940842B1 (en) | 2005-09-29 | 2012-05-30 | Merck Sharp & Dohme Corp. | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
US8163770B2 (en) | 2005-10-27 | 2012-04-24 | Msd. K. K. | Benzoxathiin derivative |
KR101318127B1 (ko) | 2005-11-10 | 2013-10-16 | 엠에스디 가부시키가이샤 | 아자 치환된 스피로 유도체 |
US7906652B2 (en) | 2005-11-28 | 2011-03-15 | Merck Sharp & Dohme Corp. | Heterocycle-substituted 3-alkyl azetidine derivatives |
AR058199A1 (es) * | 2005-11-28 | 2008-01-23 | Merck & Co Inc | Derivados de 3- alquilazetidina sustituidos con heterociclos |
US7629346B2 (en) | 2006-06-19 | 2009-12-08 | Hoffmann-La Roche Inc. | Pyrazinecarboxamide derivatives as CB1 antagonists |
MX2009001043A (es) | 2006-08-08 | 2009-02-06 | Sanofi Aventis | Imidazolidina-2,4-dionas sustituidas con arilaminoarilalquilo, procedimiento para preparalas, medicamentos que comprenden estos compuestos y su uso. |
US7781593B2 (en) | 2006-09-14 | 2010-08-24 | Hoffmann-La Roche Inc. | 5-phenyl-nicotinamide derivatives |
WO2008039327A2 (en) | 2006-09-22 | 2008-04-03 | Merck & Co., Inc. | Method of treatment using fatty acid synthesis inhibitors |
EP2072519A4 (en) | 2006-09-28 | 2009-10-21 | Banyu Pharma Co Ltd | DIARYLKETIMINDERIVAT |
US8106086B2 (en) | 2007-04-02 | 2012-01-31 | Msd K.K. | Indoledione derivative |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
WO2008151257A2 (en) | 2007-06-04 | 2008-12-11 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
FR2925050B1 (fr) * | 2007-12-14 | 2010-01-08 | Sanofi Aventis | Nouveau procede de preparation de derives d'azetidine |
PT2234966E (pt) * | 2007-12-18 | 2013-12-19 | Sanofi Sa | Derivados de azetidinas, sua preparação e sua aplicação em terapia |
FR2930941B1 (fr) * | 2008-05-06 | 2010-06-18 | Sanofi Aventis | Derives d'azetidines, leur preparation et leur application en therapeutique |
FR2928149B1 (fr) | 2008-02-29 | 2011-01-14 | Sanofi Aventis | Composes derives d'azetidines, leur preparation et leur application en therapeutique |
CN101981025A (zh) | 2008-03-28 | 2011-02-23 | 万有制药株式会社 | 具有黑色素浓缩激素受体拮抗作用的二芳基甲基酰胺衍生物 |
WO2009149279A2 (en) | 2008-06-04 | 2009-12-10 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
JPWO2009154132A1 (ja) | 2008-06-19 | 2011-12-01 | Msd株式会社 | スピロジアミン−ジアリールケトオキシム誘導体 |
WO2010009319A2 (en) | 2008-07-16 | 2010-01-21 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
EP2319841A1 (en) | 2008-07-30 | 2011-05-11 | Msd K.K. | (5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative |
FR2934996B1 (fr) * | 2008-08-14 | 2010-08-27 | Sanofi Aventis | Composes polysubstitues d'azetidines, leur preparation et leur application en therapeutique |
FR2934995B1 (fr) * | 2008-08-14 | 2010-08-27 | Sanofi Aventis | Composes d'azetidines polysubstitues, leur preparation et leur application en therapeutique |
WO2010047982A1 (en) | 2008-10-22 | 2010-04-29 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
EA201170624A1 (ru) | 2008-10-30 | 2011-12-30 | Мерк Шарп Энд Домэ Корп. | Изоникотинамидные антагонисты рецепторов орексинов |
WO2010051206A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
JP5514831B2 (ja) | 2008-11-17 | 2014-06-04 | メルク・シャープ・アンド・ドーム・コーポレーション | 糖尿病の治療のための置換二環式アミン |
FR2946650B1 (fr) | 2009-06-16 | 2011-08-19 | Sanofi Aventis | Esters derives d'azetidines, leur preparation et leur application en therapeutique. |
WO2011011506A1 (en) | 2009-07-23 | 2011-01-27 | Schering Corporation | Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
US20120220567A1 (en) | 2009-07-23 | 2012-08-30 | Shipps Jr Gerald W | Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
ES2443016T3 (es) | 2009-08-26 | 2014-02-17 | Sanofi | Nuevos hidratos cristalinos de fluoroglicósidos heteroaromáticos, productos farmacéuticos que comprenden estos compuestos, y su empleo |
AU2011218830B2 (en) | 2010-02-25 | 2014-07-24 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
US8785634B2 (en) | 2010-04-26 | 2014-07-22 | Merck Sharp & Dohme Corp | Spiropiperidine prolylcarboxypeptidase inhibitors |
WO2011143057A1 (en) | 2010-05-11 | 2011-11-17 | Merck Sharp & Dohme Corp. | Novel prolylcarboxypeptidase inhibitors |
US9006268B2 (en) | 2010-06-11 | 2015-04-14 | Merck Sharp & Dohme Corp. | Prolylcarboxypeptidase inhibitors |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
US8410107B2 (en) | 2010-10-15 | 2013-04-02 | Hoffmann-La Roche Inc. | N-pyridin-3-yl or N-pyrazin-2-yl carboxamides |
US8669254B2 (en) | 2010-12-15 | 2014-03-11 | Hoffman-La Roche Inc. | Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents |
CN103476258B (zh) | 2011-02-25 | 2017-04-26 | 默沙东公司 | 用作抗糖尿病药剂的新的环状氮杂苯并咪唑衍生物 |
WO2012120057A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
EP2683702B1 (de) | 2011-03-08 | 2014-12-24 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2012120051A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
US8846666B2 (en) | 2011-03-08 | 2014-09-30 | Sanofi | Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
AR088352A1 (es) | 2011-10-19 | 2014-05-28 | Merck Sharp & Dohme | Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina |
EP2880028B1 (en) | 2012-08-02 | 2020-09-30 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
CA2898482A1 (en) | 2013-02-22 | 2014-08-28 | Linda L. Brockunier | Antidiabetic bicyclic compounds |
EP2970119B1 (en) | 2013-03-14 | 2021-11-03 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
JP2016514671A (ja) | 2013-03-15 | 2016-05-23 | シナジー ファーマシューティカルズ インコーポレイテッド | グアニル酸シクラーゼのアゴニストおよびその使用 |
EP2968439A2 (en) | 2013-03-15 | 2016-01-20 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
CA2913737A1 (en) | 2013-06-05 | 2014-12-11 | Synergy Pharmaceuticals, Inc. | Ultra-pure agonists of guanylate cyclase c, method of making and using same |
WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
KR102431436B1 (ko) | 2014-08-29 | 2022-08-10 | 테스 파마 에스.알.엘. | α-아미노-β-카복시뮤콘산 세미알데히드 데카복실라제의 억제제 |
WO2018069532A1 (en) | 2016-10-14 | 2018-04-19 | Tes Pharma S.R.L. | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase |
EP3551176A4 (en) | 2016-12-06 | 2020-06-24 | Merck Sharp & Dohme Corp. | ANTIDIABETIC HETEROCYCLIC COMPOUNDS |
AU2019385644A1 (en) | 2018-11-20 | 2021-06-03 | Tes Pharma S.R.L. | Inhibitors of α-Amino-β-carboxymuconic acid semialdehyde decarboxylase |
EP3924058A1 (en) | 2019-02-13 | 2021-12-22 | Merck Sharp & Dohme Corp. | 5-alkyl pyrrolidine orexin receptor agonists |
US20230018413A1 (en) | 2019-08-08 | 2023-01-19 | Merck Sharp & Dohme Corp. | Heteroaryl pyrrolidine and piperidine orexin receptor agonists |
TW202227417A (zh) | 2020-08-18 | 2022-07-16 | 美商默沙東藥廠 | 雙環庚烷吡咯啶之食慾素受體促效劑 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4242261A (en) * | 1979-07-19 | 1980-12-30 | A. H. Robins Company, Inc. | Production of methylene-cycloamines |
FR2649100B1 (fr) * | 1989-06-29 | 1994-03-04 | Laboratorios Dr Esteve Sa | Nouvelles azetidines, leur preparation et leur application comme intermediaires pour la preparation de composes avec activite antimicrobienne |
US5556861A (en) * | 1991-10-01 | 1996-09-17 | Laboratoire Roger Bellon | 1,8 benzonaphthyridine derivatives and antimicrobial compositions |
CA2166975C (en) * | 1993-07-16 | 2005-04-05 | Mark G. Bock | Benzoxazinone and benzopyrimidinone piperidinyl tocolytic oxytocin receptor antagonists |
US5545636A (en) * | 1993-12-23 | 1996-08-13 | Eli Lilly And Company | Protein kinase C inhibitors |
WO1997001556A1 (en) * | 1995-06-29 | 1997-01-16 | Novo Nordisk A/S | Novel substituted azacyclic or azabicyclic compounds |
GB9714129D0 (en) * | 1997-07-04 | 1997-09-10 | Pfizer Ltd | Azetidines |
-
2000
- 2000-03-03 FR FR0002776A patent/FR2805817B1/fr not_active Expired - Fee Related
-
2001
- 2001-01-03 UA UA2002097701A patent/UA73554C2/uk unknown
- 2001-02-23 TW TW090104187A patent/TWI304399B/zh not_active IP Right Cessation
- 2001-03-01 SK SK1243-2002A patent/SK287445B6/sk not_active IP Right Cessation
- 2001-03-01 OA OA1200200270A patent/OA12222A/fr unknown
- 2001-03-01 JP JP2001563477A patent/JP4883867B2/ja not_active Expired - Fee Related
- 2001-03-01 SI SI200130981T patent/SI1263722T1/sl unknown
- 2001-03-01 EA EA200200938A patent/EA007109B1/ru not_active IP Right Cessation
- 2001-03-01 BR BRPI0108893-9A patent/BR0108893B1/pt not_active IP Right Cessation
- 2001-03-01 ES ES01909939T patent/ES2351276T3/es not_active Expired - Lifetime
- 2001-03-01 AU AU37527/01A patent/AU780880B2/en not_active Ceased
- 2001-03-01 PL PL365046A patent/PL208021B1/pl unknown
- 2001-03-01 DE DE60142891T patent/DE60142891D1/de not_active Expired - Lifetime
- 2001-03-01 MX MXPA02008349A patent/MXPA02008349A/es active IP Right Grant
- 2001-03-01 WO PCT/FR2001/000602 patent/WO2001064634A1/fr active IP Right Grant
- 2001-03-01 YU YU66002A patent/YU66002A/sh unknown
- 2001-03-01 DK DK01909939.9T patent/DK1263722T3/da active
- 2001-03-01 NZ NZ521077A patent/NZ521077A/en unknown
- 2001-03-01 CA CA2400141A patent/CA2400141C/fr not_active Expired - Fee Related
- 2001-03-01 KR KR1020027011517A patent/KR100819572B1/ko not_active IP Right Cessation
- 2001-03-01 CZ CZ20022923A patent/CZ301254B6/cs not_active IP Right Cessation
- 2001-03-01 DZ DZ013312A patent/DZ3312A1/fr active
- 2001-03-01 HU HU0400636A patent/HUP0400636A3/hu unknown
- 2001-03-01 ME MEP-95/09A patent/MEP9509A/xx unknown
- 2001-03-01 EE EEP200200485A patent/EE05103B1/xx not_active IP Right Cessation
- 2001-03-01 EP EP01909939A patent/EP1263722B1/fr not_active Expired - Lifetime
- 2001-03-01 CN CNB018066437A patent/CN100386314C/zh not_active Expired - Fee Related
- 2001-03-01 AT AT01909939T patent/ATE478841T1/de active
- 2001-03-01 IL IL15132101A patent/IL151321A0/xx unknown
- 2001-03-01 PT PT01909939T patent/PT1263722E/pt unknown
-
2002
- 2002-08-18 IL IL151321A patent/IL151321A/en not_active IP Right Cessation
- 2002-08-28 MA MA26794A patent/MA26880A1/fr unknown
- 2002-08-28 ZA ZA200206912A patent/ZA200206912B/en unknown
- 2002-08-30 HR HRP20020712AA patent/HRP20020712B1/hr not_active IP Right Cessation
- 2002-09-02 NO NO20024177A patent/NO324524B1/no not_active IP Right Cessation
- 2002-09-03 BG BG107058A patent/BG66001B1/bg unknown
-
2010
- 2010-11-18 CY CY20101101042T patent/CY1111071T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1111071T1 (el) | Φαρμακευτικες ενωσεις που περιεχουν τα παραγωγα αζετιδινης, τα νεα παραγωγα αζετιδινης και η παρασκευη τους | |
CY1105301T1 (el) | Αρυλοσυμπυκνωμενες αζαπολυκυκλικες ενωσεις | |
YU65802A (sh) | Derivati azetidina, njihovo dobivanje i farmaceutske smeše koje ih sadrže | |
CY1109655T1 (el) | Συνδεση των παραγωγων κινουκλιδινης στους μουσκαρινικους υποδοχεις μ3 | |
DE60107449D1 (de) | Substituierte aminopropoxyarylderivate als lxr agonisten | |
EA199900937A1 (ru) | Фармацевтические композиции, содержащие вориконазол | |
CY1108019T1 (el) | Ενωσεις πυριμιδινης | |
TR200200579T2 (tr) | Amino-tirazolpiridin türevleri. | |
CY1105387T1 (el) | Υποκατεστημενα παραγωγα 2-διαλκυλαμινοαλκυλοδιφαινθλιου | |
EA200300937A1 (ru) | Оральная фармацевтическая композиция цефподоксима проксетила | |
NO20052074L (no) | Substituerte benzoksazinoner og anvendelser derav. | |
NO20015172L (no) | 1-metyl-erytromycin-derivater | |
CY1110694T1 (el) | Μεθοδος παρασκευης παραγωγων της εχινοκανδινης | |
DK1181299T3 (da) | C-2-modificerede erythromycinderivater | |
ATE299871T1 (de) | Neue zyklische depsipeptid pf1022 derivate | |
PT992509E (pt) | Novos derivados macrolidos | |
EA200000431A2 (ru) | Новые замещенные димерные соединения, способ их получения и фармацевтические композиции, содержащие их | |
MY138466A (en) | Aminoalkoxyndoles as 5-ht6-receptor ligands for the treatment of cns-disorders | |
ATE453389T1 (de) | Bestimmte pharmazeutisch wertvolle substituierte aminoalkyl-heterocyclen | |
BR0104358A (pt) | Formulações de taxana tendo solubilidade aperfeiçoada | |
DE69933885D1 (de) | Triphenylbutenderivate zur behandlung von neurologischen störungen | |
BR0209901A (pt) | Processos para a sìntese de derivados de 2,3-dihidro-1,4-dioxino-[2,3-f] quinolina | |
DE69917005D1 (de) | Substituierte pyrrolobenzimidazolderivate zur entzündungshemmung | |
TR200402546T4 (tr) | Taksan türevleri hazırlamak için işlem. | |
AR035406A1 (es) | Procedimiento de preparacion de eletriptan |